Oculis Holding AG (OCS) stock
OCSNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as OCSAW
$7.64+0.14 (+1.87%)
Close on Nov 13, 2026Market cap $459.08MP/E –Yield –
Oculis r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was CHF 57.09M, up 9.6% from the year before. The highest annual figure on record is CHF 57.09M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | CHF 57.09M | +9.6% |
| FY2024 | Dec 31, 2024 | CHF 52.08M | +78.1% |
| FY2023 | Dec 31, 2023 | CHF 29.25M | +31.6% |
| FY2022 | Dec 31, 2022 | CHF 22.22M | +132.3% |
| FY2021 | Dec 31, 2021 | CHF 9.57M | +2.5% |
| FY2020 | Dec 31, 2020 | CHF 9.34M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | CHF 15.28M | – |
| Q2 FY2025 | Jun 30, 2025 | CHF 14.91M | – |
| Q2 FY2024 | Jun 30, 2024 | CHF 16.47M | – |
| Q2 FY2023 | Jun 30, 2023 | CHF 6.20M | – |
See a number that looks wrong?